[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.176.107. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
January 27, 1993

Antineoplastons: The Controversy Continues

Author Affiliations

New York, NY

JAMA. 1993;269(4):475-476. doi:10.1001/jama.1993.03500040041028
Abstract

To the Editor.  —As a medical writer who has investigated antineoplastons, I found that numerous assertions in the article by Dr Green1 appear to be at odds with the documentation. He claims, for example, that "none of the independent tests... have shown anticancer activity." Yet his article cites three independent animal studies (references 18 through 20) from Japan and the United States regarding tumor inhibition by antineoplastons. Focusing on letters, Green ignores these published results.Also ignored were the results of published clinical studies by Dr Burzynski (references 7 and 33). Green repeatedly misstates the work of Burzynski. Contrary to Green, I found Burzynki's 1968 doctoral dissertation in biochemistry listed in the bibliography that Green claims omits it.The article concludes that phenylacetic acid, a component of the therapy, is not active against cancer. Yet scientists at the NCI have reported that phenylacetate is a "nontoxic inducer of tumor

×